外周血自然杀伤细胞比例在原发免疫性血小板减少症中临床意义

申星, 程芳芳, 常舒婷, 等. 外周血自然杀伤细胞比例在原发免疫性血小板减少症中临床意义[J]. 临床血液学杂志, 2019, 32(1): 48-51. doi: 10.13201/j.issn.1004-2806.2019.01.013
引用本文: 申星, 程芳芳, 常舒婷, 等. 外周血自然杀伤细胞比例在原发免疫性血小板减少症中临床意义[J]. 临床血液学杂志, 2019, 32(1): 48-51. doi: 10.13201/j.issn.1004-2806.2019.01.013
SHEN Xing, CHENG Fangfang, CHANG Shuting, et al. Clinical significance of peripheral blood NK cell ratio in primary immune thrombocytopenia[J]. J Clin Hematol, 2019, 32(1): 48-51. doi: 10.13201/j.issn.1004-2806.2019.01.013
Citation: SHEN Xing, CHENG Fangfang, CHANG Shuting, et al. Clinical significance of peripheral blood NK cell ratio in primary immune thrombocytopenia[J]. J Clin Hematol, 2019, 32(1): 48-51. doi: 10.13201/j.issn.1004-2806.2019.01.013

外周血自然杀伤细胞比例在原发免疫性血小板减少症中临床意义

详细信息
    通讯作者: 杨林花,E-mail:yanglh5282@163.com
  • 中图分类号: R554.1

Clinical significance of peripheral blood NK cell ratio in primary immune thrombocytopenia

More Information
  • 目的:探讨原发免疫性血小板减少症(ITP)患者初诊时外周血淋巴细胞亚群中自然杀伤(NK)细胞比例在ITP中的临床意义。方法:收集149例初诊ITP患者的临床资料,依据NK细胞比例分为NK细胞比例降低组(89例)、正常组(56例)及升高组(4例),分别记录3组患者年龄、性别、血小板计数、淋巴细胞数、治疗前辅助性T细胞(Th细胞)、抑制性T细胞(Ts细胞)、NK细胞、CD19+细胞比例及出血评分,比较各组患者临床特点。总结各组患者治疗起效时间、完全反应时间及复发时间,比较不同组别的疗效及预后。结果:①3组患者治疗前血小板计数、淋巴细胞数、Th细胞、Ts细胞、CD19+细胞百分比均差异无统计学意义(均P>0.05)。分别个体化给予不同治疗方案,中位随访时间为5(2~60)个月,3组患者临床疗效比较均差异无统计学意义(均P>0.05)。②年龄与治疗前Th细胞比例、出血评分存在正相关关系(r=0.175、0.206),Ts细胞比例与Th细胞、NK细胞及CD19+细胞比例呈负相关(r=-0.501、-0.247、-0.355)。结论:NK细胞比例降低与ITP的发病有一定相关性,老年患者出血风险更高。检测外周血NK细胞比例对临床上ITP的诊治具有重要指导意义。
  • 加载中
  • [1]

    Kashiwagi H, Tomiyama Y.Pathophysiology and management of primary immune thrombocytopenia[J].Int J Hematol, 2013, 98:24-33.

    [2]

    Cines DB, Bussel JB, Liebman HA, et al.The ITP syndrome:pathogenic and clinical diversity[J].Blood, 2009, 113:6511-6521.

    [3]

    Olsson B, Andersson PO, Jernas M, et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Nat Med, 2003, 9:1123-1124.

    [4]

    Mckenzie CG, Guo L, Freedman J, et al.Cellular immune dysfunction in immune thrombocytopenia (ITP)[J].Br J Haematol, 2013, 163:10-23.

    [5]

    Yang L, Wang L, Zhao C, et al.Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia[J].Blood, 2010, 116:4307-4316.

    [6]

    Park YW, Kee SJ, Cho YN, et al.Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus[J].Arthritis Rheumatol, 2009, 60:1753-1763.

    [7]

    Leavenworth JW, Wang X, Wenander CS, et al.Mobilization of natural killer cells inhibits development of collagen-induced arthritis[J].Proc Natl Acad Sci U S A, 2011, 108:14584-14589.

    [8]

    Liu C, Li Z, Sheng W, et al.Abnormalities of quantities and functions of natural killer cells in severe aplastic anemia[J].Immunol Invest, 2014, 43:491-503.

    [9]

    Zhang Y, Lv G, Lou X, et al.NKG2A expression and impaired function of NK cells in patients with new onset of Graves'disease[J].Int Immunopharmacol, 2015, 24:133-139.

    [10]

    Zhao Z, Yang L, Yang G, et al.Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia[J].PLos One, 2015, 10:e0126601.

    [11]

    Talaat RM, Elmaghraby AM, Barakat SS, et al.Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrumbocytopenic purpura (ITP)[J].Clin Exp Imnmnol, 2014, 176:291-300.

    [12]

    Ebbo M, Audonnet S, Grados A, et al.NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia[J].Clin Immunol, 2017, 177:18-28.

    [13]

    Provan D, Stasi R, Newland AC, et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood, 2010, 115:168-186.

    [14]

    Liu XG, Hou M.Immune thrombocytopenia and Bcell-activating factor/a proliferation-inducing ligand[J].Semin Hematol, 2013, 50:89-99.

    [15]

    Zhou Z, Li X, Li J, et al.Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients[J].J Clin Immunol, 2010, 30:814-822.

    [16]

    Stasi R.Immune thmmbocytopenia:pathophysiologic and clinical update[J].Semin Thromb Hemost, 2012, 38:454-462.

    [17]

    Yu J, Freud AG, Caligiuri MA.Location and cellular stages of natural killer cell development[J].Trends Immunol, 2013, 34:573-573.

    [18]

    Tian Z, Gershwin ME, Zhang C.Regulatory NK cells in autoimmune disease[J].J Autoimmun, 2012, 39:206-215.

    [19]

    王明镜, 胡晓梅, 邓中阳, 等.免疫性血小板减少症的免疫机制研究进展[J].临床血液学杂志, 2017, 30 (9):725-728.

    [20]

    张玉娇, 瞿文, 刘惠, 等.免疫性血小板减少症患者NK细胞数量及功能[J].中华医学杂志, 2017, 97 (16):1231-1235.

  • 加载中
计量
  • 文章访问数:  252
  • PDF下载数:  78
  • 施引文献:  0
出版历程
收稿日期:  2018-11-26

目录